Oragenics, Inc. (OGEN) 10-Year Financial Performance & Capital Metrics

OGEN • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutOragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Show more

Revenue $0
EBITDA -$11M +49.5%
Net Income -$11M +48.8%
EPS (Diluted) -1.60 +82.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -714.95% -180.0%
ROIC -
Debt/Equity -
Interest Coverage -353.99

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM45.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40.86%

ROCE

10Y Avg-194.2%

5Y Avg-253.05%

3Y Avg-347.52%

Latest-714.33%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.18M	0	0	0	0	0	0	0	0	0
Revenue Growth %	0.25%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	481.74K	75.04K	65.8K	30.11K	62.62K	22.11M	0	0	0	0
COGS % of Revenue	0.41%	-	-	-	-	-	-	-	-	-
Gross Profit+	694.1K	-75.04K	-65.8K	-30.11K	-62.62K	-22.11M	0	0	0	0
Gross Margin %	0.59%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.22%	-1.11%	0.12%	0.54%	-1.08%	-352.03%	1%	-	-	-
Operating Expenses+	12.35M	8.54M	6.72M	9.99M	15.88M	4.53M	15.77M	14.42M	20.9M	10.56M
OpEx % of Revenue	10.5%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.54M	3.79M	3.18M	4.02M	3.76M	4.53M	5.27M	4.48M	5.45M	6.44M
SG&A % of Revenue	3.01%	-	-	-	-	-	-	-	-	-
Research & Development	8.8M	4.75M	3.54M	5.97M	12.12M	22.11M	10.59M	10.07M	15.49M	4.11M
R&D % of Revenue	7.49%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-4.7K	-4.8K	-3.1K	446	2K	-22.11M	-86.99K	-131.52K	-37.65K	0
Operating Income+	-11.65M	-8.54M	-6.72M	-9.99M	-15.88M	-26.64M	-15.77M	-14.42M	-20.9M	-10.56M
Operating Margin %	-9.91%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1%	0.27%	0.21%	-0.49%	-0.59%	-0.68%	0.41%	0.09%	-0.45%	0.49%
EBITDA+	-11.58M	-8.47M	-6.65M	-9.96M	-15.82M	-26.59M	-15.73M	-14.38M	-20.88M	-10.54M
EBITDA Margin %	-9.85%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1%	0.27%	0.21%	-0.5%	-0.59%	-0.68%	0.41%	0.09%	-0.45%	0.5%
D&A (Non-Cash Add-back)	71.15K	75.04K	65.8K	30.11K	62.62K	51.7K	41.24K	44.67K	27.39K	0
EBIT	-11.76M	-8.49M	-6.72M	-9.91M	-15.56M	-26.64M	-15.7M	-14.27M	-20.63M	-10.54M
Net Interest Income+	-55.29K	35.97K	-206.11K	80.74K	312.71K	78.61K	60.09K	120.8K	179.8K	16.07K
Interest Income	21.38K	40.09K	10.22K	86.53K	320.01K	89.29K	75.85K	135.9K	179.8K	45.9K
Interest Expense	76.67K	4.12K	216.33K	5.79K	7.3K	10.69K	15.76K	15.1K	0	29.83K
Other Income/Expense	-59.21K	45.19K	-13.21K	80K	311.57K	210.76K	59.4K	132.38K	249.17K	-9.1K
Pretax Income+	-11.84M	-8.5M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Pretax Margin %	-10.07%	-	-	-	-	-	-	-	-	-
Income Tax+	59.21K	0	13.21K	-80K	7.76K	0	0	0	0	0
Effective Tax Rate %	0.99%	0.83%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.71M	-7.01M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Net Margin %	-9.96%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.02%	0.4%	0.04%	-0.47%	-0.57%	-0.7%	0.41%	0.09%	-0.45%	0.49%
Net Income (Continuing)	-11.84M	-8.5M	-6.73M	-9.91M	0	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Discontinued Operations	128.75K	1.48M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-192.00	-94.33	-81.99	-45.62	-22.10	-28.05	-8.09	-7.11	-9.18	-1.60
EPS Growth %	-1%	0.51%	0.13%	0.44%	0.52%	-0.27%	0.71%	0.12%	-0.29%	0.83%
EPS (Basic)	-192.00	-94.35	-81.99	-45.62	-22.10	-28.05	-8.09	-7.11	-9.18	-1.60
Diluted Shares Outstanding	61.09K	74.35K	82.1K	217.32K	704.73K	942.19K	1.88M	2.01M	2.25M	6.62M
Basic Shares Outstanding	61.09K	74.33K	82.1K	217.32K	704.73K	942.19K	1.88M	2.01M	2.25M	6.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.64M	4.22M	7.19M	21.93M	18.84M	17.98M	27.71M	14.29M	3.87M	1.47M
Cash & Short-Term Investments	5.08M	4.08M	6.17M	20.21M	18.27M	17.64M	27.27M	11.43M	3.48M	864.84K
Cash Only	5.08M	4.08M	6.17M	20.21M	18.27M	17.64M	27.27M	11.43M	3.48M	864.84K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	21.11K	0	0	0	0	0	6.99K	0	0	0
Days Sales Outstanding	6.55	-	-	-	-	-	-	-	-	-
Inventory	321.51K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	243.6	-	-	-	-	-	-	-	-	-
Other Current Assets	2.45K	0	1.03M	1.72M	0	0	0	0	0	0
Total Non-Current Assets+	140.65K	87.46K	21.66K	116.28K	914.65K	697.85K	523.59K	468.5K	1.1M	0
Property, Plant & Equipment	140.65K	87.46K	21.66K	116.28K	914.65K	697.85K	523.59K	468.5K	9.81K	0
Fixed Asset Turnover	8.36x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	30.56K	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	-30.56K	0	0	0	0	0	0	1.09M	0
Total Assets+	5.78M	4.31M	7.21M	22.05M	19.75M	18.68M	28.23M	14.76M	4.97M	1.47M
Asset Turnover	0.20x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.48%	-0.25%	0.67%	2.06%	-0.1%	-0.05%	0.51%	-0.48%	-0.66%	-0.7%
Total Current Liabilities+	1.05M	1.34M	898.52K	1.17M	1.85M	1.34M	1.45M	1.6M	1.8M	1.68M
Accounts Payable	280K	461.34K	618.36K	828.71K	1.21M	330.38K	854.98K	246.69K	1.24M	1.14M
Days Payables Outstanding	212.14	2.24K	3.43K	10.05K	7.04K	5.45	-	-	-	-
Short-Term Debt	63.35K	66.38K	80.48K	124.21K	143.86K	228.23K	303.42K	267.64K	312.7K	328.53K
Deferred Revenue (Current)	14.21K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	232.18K	524.62K	42.96K	39.61K	143.09K	158.72K	57.73K	843.96K	0	202.83K
Current Ratio	5.38x	3.14x	8.01x	18.79x	10.18x	13.40x	19.17x	8.95x	2.15x	0.87x
Quick Ratio	5.08x	3.14x	8.01x	18.79x	10.18x	13.40x	19.17x	8.95x	2.15x	0.87x
Cash Conversion Cycle	38.01	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	461.45K	527.72K	698.84K	952.92K	670.69K	493.79K	299.52K	152.44K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	670.69K	493.79K	299.52K	152.44K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.05M	1.34M	898.52K	1.17M	2.52M	1.84M	1.74M	1.75M	1.8M	1.68M
Total Debt+	63.35K	66.38K	80.48K	124.21K	979.65K	898.92K	797.21K	624.53K	322.51K	328.53K
Net Debt	-5.02M	-4.01M	-6.09M	-20.08M	-17.29M	-16.74M	-26.47M	-10.8M	-3.16M	-536.31K
Debt / Equity	0.01x	0.02x	0.01x	0.01x	0.06x	0.05x	0.03x	0.05x	0.10x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-151.98x	-2075.44x	-31.06x	-1727.27x	-2175.07x	-2493.35x	-1000.95x	-954.83x	-	-353.99x
Total Equity+	4.73M	2.97M	6.32M	20.88M	17.23M	16.84M	26.49M	13.01M	3.17M	-211.88K
Equity Growth %	-0.54%	-0.37%	1.13%	2.31%	-0.17%	-0.02%	0.57%	-0.51%	-0.76%	-1.07%
Book Value per Share	77.44	39.89	76.93	96.09	24.45	17.88	14.07	6.48	1.41	-0.03
Total Shareholders' Equity	4.73M	2.97M	6.32M	20.88M	17.23M	16.84M	26.49M	13.01M	3.17M	-211.88K
Common Stock	39.86K	49.11K	4.93K	29.43K	46.13K	91.77K	116.39K	2.02K	3.08K	12.57K
Retained Earnings	-87.66M	-94.67M	-101.4M	-111.37M	-127.35M	-154.44M	-171.27M	-185.56M	-206.22M	-216.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.45M	-1.52M	-1.58M	-1.61M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.1M	-7.08M	-6.36M	-9.08M	-13.01M	-16.95M	-13.47M	-15.23M	-7.29M	-8.6M
Operating CF Margin %	-4.34%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.08%	-0.39%	0.1%	-0.43%	-0.43%	-0.3%	0.21%	-0.13%	0.52%	-0.18%
Net Income	-11.71M	-7.01M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Depreciation & Amortization	71.15K	75.04K	65.8K	30.11K	62.62K	51.7K	41.24K	44.67K	27.39K	0
Stock-Based Compensation	1.03M	638.42K	560.48K	1.02M	553K	1.49M	1.69M	742.2K	1.02M	516.05K
Deferred Taxes	-1.28K	3.13K	0	0	0	0	-1.77M	0	0	0
Other Non-Cash Items	5M	-1.45M	-70.49K	12K	12K	7.9M	1.77M	-10.96K	10.3M	0
Working Capital Changes	502.37K	675.38K	-188.12K	-228.14K	1.93M	37.02K	512.14K	-1.72M	2.02M	1.45M
Change in Receivables	-5.51K	0	0	0	0	0	-6.99K	6.99K	0	0
Change in Inventory	117.68K	0	0	0	0	0	6.99K	0	0	0
Change in Payables	331.08K	446.04K	525.78K	225.31K	0	0	10.55K	0	0	-119.8K
Cash from Investing+	-101.23K	1.68M	0	-124.73K	-25.21K	0	-43.88K	-115.52K	-936.28K	0
Capital Expenditures	-102.51K	-27.18K	0	-124.73K	-25.21K	0	-43.88K	-127.52K	-1M	0
CapEx % of Revenue	0.09%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.28K	1.7M	0	0	0	0	0	12K	63.72K	0
Cash from Financing+	-159.95K	4.45M	8.45M	23.25M	11.1M	16.32M	23.14M	-494.92K	283.88K	5.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-58.67K	0	0	-1.12M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	1.97M	6.21M	23.31M	11.35M	5.18M	1.12M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.21M	-7.1M	-6.36M	-9.2M	-13.04M	-16.95M	-13.51M	-15.36M	-8.29M	-8.6M
FCF Margin %	-4.43%	-	-	-	-	-	-	-	-	-
FCF Growth %	0.08%	-0.36%	0.1%	-0.45%	-0.42%	-0.3%	0.2%	-0.14%	0.46%	-0.04%
FCF per Share	-85.23	-95.53	-77.51	-42.36	-18.50	-17.99	-7.18	-7.64	-3.68	-1.30
FCF Conversion (FCF/Net Income)	0.44x	1.01x	0.95x	0.92x	0.84x	0.64x	0.86x	1.07x	0.35x	0.81x
Interest Paid	0	0	0	0	7.3K	10.02K	0	9.29K	30.59K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.45%	-182.24%	-145.04%	-72.9%	-81.72%	-155.13%	-72.52%	-72.35%	-255.36%	-714.95%
Return on Invested Capital (ROIC)	-	-	-2184.64%	-1457.5%	-3213.29%	-84585%	-19448.14%	-972.3%	-1416.19%	-
Gross Margin	59.02%	-	-	-	-	-	-	-	-	-
Net Margin	-995.83%	-	-	-	-	-	-	-	-	-
Debt / Equity	0.01x	0.02x	0.01x	0.01x	0.06x	0.05x	0.03x	0.05x	0.10x	-
Interest Coverage	-151.98x	-2075.44x	-31.06x	-1727.27x	-2175.07x	-2493.35x	-1000.95x	-954.83x	-	-353.99x
FCF Conversion	0.44x	1.01x	0.95x	0.92x	0.84x	0.64x	0.86x	1.07x	0.35x	0.81x
Revenue Growth	25.12%	-100%	-	-	-	-	-	-	-	-

Revenue by Segment

	2022	2023
Grant	250K	250K
Grant Growth	-	0.00%

Frequently Asked Questions

Growth & Financials

Oragenics, Inc. (OGEN) grew revenue by 0.0% over the past year. Growth has been modest.

Oragenics, Inc. (OGEN) reported a net loss of $10.9M for fiscal year 2024.

Dividend & Returns

Oragenics, Inc. (OGEN) has a return on equity (ROE) of -714.9%. Negative ROE indicates the company is unprofitable.

Oragenics, Inc. (OGEN) had negative free cash flow of $8.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Oragenics, Inc. (OGEN) 10-Year Financial Performance & Capital Metrics

OGEN • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $0
EBITDA -$11M +49.5%
Net Income -$11M +48.8%
EPS (Diluted) -1.60 +82.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -714.95% -180.0%
ROIC -
Debt/Equity -
Interest Coverage -353.99

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM45.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM-40.86%

ROCE

10Y Avg-194.2%

5Y Avg-253.05%

3Y Avg-347.52%

Latest-714.33%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.18M	0	0	0	0	0	0	0	0	0
Revenue Growth %	0.25%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	481.74K	75.04K	65.8K	30.11K	62.62K	22.11M	0	0	0	0
COGS % of Revenue	0.41%	-	-	-	-	-	-	-	-	-
Gross Profit+	694.1K	-75.04K	-65.8K	-30.11K	-62.62K	-22.11M	0	0	0	0
Gross Margin %	0.59%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	0.22%	-1.11%	0.12%	0.54%	-1.08%	-352.03%	1%	-	-	-
Operating Expenses+	12.35M	8.54M	6.72M	9.99M	15.88M	4.53M	15.77M	14.42M	20.9M	10.56M
OpEx % of Revenue	10.5%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.54M	3.79M	3.18M	4.02M	3.76M	4.53M	5.27M	4.48M	5.45M	6.44M
SG&A % of Revenue	3.01%	-	-	-	-	-	-	-	-	-
Research & Development	8.8M	4.75M	3.54M	5.97M	12.12M	22.11M	10.59M	10.07M	15.49M	4.11M
R&D % of Revenue	7.49%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-4.7K	-4.8K	-3.1K	446	2K	-22.11M	-86.99K	-131.52K	-37.65K	0
Operating Income+	-11.65M	-8.54M	-6.72M	-9.99M	-15.88M	-26.64M	-15.77M	-14.42M	-20.9M	-10.56M
Operating Margin %	-9.91%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1%	0.27%	0.21%	-0.49%	-0.59%	-0.68%	0.41%	0.09%	-0.45%	0.49%
EBITDA+	-11.58M	-8.47M	-6.65M	-9.96M	-15.82M	-26.59M	-15.73M	-14.38M	-20.88M	-10.54M
EBITDA Margin %	-9.85%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1%	0.27%	0.21%	-0.5%	-0.59%	-0.68%	0.41%	0.09%	-0.45%	0.5%
D&A (Non-Cash Add-back)	71.15K	75.04K	65.8K	30.11K	62.62K	51.7K	41.24K	44.67K	27.39K	0
EBIT	-11.76M	-8.49M	-6.72M	-9.91M	-15.56M	-26.64M	-15.7M	-14.27M	-20.63M	-10.54M
Net Interest Income+	-55.29K	35.97K	-206.11K	80.74K	312.71K	78.61K	60.09K	120.8K	179.8K	16.07K
Interest Income	21.38K	40.09K	10.22K	86.53K	320.01K	89.29K	75.85K	135.9K	179.8K	45.9K
Interest Expense	76.67K	4.12K	216.33K	5.79K	7.3K	10.69K	15.76K	15.1K	0	29.83K
Other Income/Expense	-59.21K	45.19K	-13.21K	80K	311.57K	210.76K	59.4K	132.38K	249.17K	-9.1K
Pretax Income+	-11.84M	-8.5M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Pretax Margin %	-10.07%	-	-	-	-	-	-	-	-	-
Income Tax+	59.21K	0	13.21K	-80K	7.76K	0	0	0	0	0
Effective Tax Rate %	0.99%	0.83%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.71M	-7.01M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Net Margin %	-9.96%	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.02%	0.4%	0.04%	-0.47%	-0.57%	-0.7%	0.41%	0.09%	-0.45%	0.49%
Net Income (Continuing)	-11.84M	-8.5M	-6.73M	-9.91M	0	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Discontinued Operations	128.75K	1.48M	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-192.00	-94.33	-81.99	-45.62	-22.10	-28.05	-8.09	-7.11	-9.18	-1.60
EPS Growth %	-1%	0.51%	0.13%	0.44%	0.52%	-0.27%	0.71%	0.12%	-0.29%	0.83%
EPS (Basic)	-192.00	-94.35	-81.99	-45.62	-22.10	-28.05	-8.09	-7.11	-9.18	-1.60
Diluted Shares Outstanding	61.09K	74.35K	82.1K	217.32K	704.73K	942.19K	1.88M	2.01M	2.25M	6.62M
Basic Shares Outstanding	61.09K	74.33K	82.1K	217.32K	704.73K	942.19K	1.88M	2.01M	2.25M	6.62M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.64M	4.22M	7.19M	21.93M	18.84M	17.98M	27.71M	14.29M	3.87M	1.47M
Cash & Short-Term Investments	5.08M	4.08M	6.17M	20.21M	18.27M	17.64M	27.27M	11.43M	3.48M	864.84K
Cash Only	5.08M	4.08M	6.17M	20.21M	18.27M	17.64M	27.27M	11.43M	3.48M	864.84K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	21.11K	0	0	0	0	0	6.99K	0	0	0
Days Sales Outstanding	6.55	-	-	-	-	-	-	-	-	-
Inventory	321.51K	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	243.6	-	-	-	-	-	-	-	-	-
Other Current Assets	2.45K	0	1.03M	1.72M	0	0	0	0	0	0
Total Non-Current Assets+	140.65K	87.46K	21.66K	116.28K	914.65K	697.85K	523.59K	468.5K	1.1M	0
Property, Plant & Equipment	140.65K	87.46K	21.66K	116.28K	914.65K	697.85K	523.59K	468.5K	9.81K	0
Fixed Asset Turnover	8.36x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	30.56K	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	-30.56K	0	0	0	0	0	0	1.09M	0
Total Assets+	5.78M	4.31M	7.21M	22.05M	19.75M	18.68M	28.23M	14.76M	4.97M	1.47M
Asset Turnover	0.20x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.48%	-0.25%	0.67%	2.06%	-0.1%	-0.05%	0.51%	-0.48%	-0.66%	-0.7%
Total Current Liabilities+	1.05M	1.34M	898.52K	1.17M	1.85M	1.34M	1.45M	1.6M	1.8M	1.68M
Accounts Payable	280K	461.34K	618.36K	828.71K	1.21M	330.38K	854.98K	246.69K	1.24M	1.14M
Days Payables Outstanding	212.14	2.24K	3.43K	10.05K	7.04K	5.45	-	-	-	-
Short-Term Debt	63.35K	66.38K	80.48K	124.21K	143.86K	228.23K	303.42K	267.64K	312.7K	328.53K
Deferred Revenue (Current)	14.21K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	232.18K	524.62K	42.96K	39.61K	143.09K	158.72K	57.73K	843.96K	0	202.83K
Current Ratio	5.38x	3.14x	8.01x	18.79x	10.18x	13.40x	19.17x	8.95x	2.15x	0.87x
Quick Ratio	5.08x	3.14x	8.01x	18.79x	10.18x	13.40x	19.17x	8.95x	2.15x	0.87x
Cash Conversion Cycle	38.01	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	461.45K	527.72K	698.84K	952.92K	670.69K	493.79K	299.52K	152.44K	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	670.69K	493.79K	299.52K	152.44K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	1.05M	1.34M	898.52K	1.17M	2.52M	1.84M	1.74M	1.75M	1.8M	1.68M
Total Debt+	63.35K	66.38K	80.48K	124.21K	979.65K	898.92K	797.21K	624.53K	322.51K	328.53K
Net Debt	-5.02M	-4.01M	-6.09M	-20.08M	-17.29M	-16.74M	-26.47M	-10.8M	-3.16M	-536.31K
Debt / Equity	0.01x	0.02x	0.01x	0.01x	0.06x	0.05x	0.03x	0.05x	0.10x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-151.98x	-2075.44x	-31.06x	-1727.27x	-2175.07x	-2493.35x	-1000.95x	-954.83x	-	-353.99x
Total Equity+	4.73M	2.97M	6.32M	20.88M	17.23M	16.84M	26.49M	13.01M	3.17M	-211.88K
Equity Growth %	-0.54%	-0.37%	1.13%	2.31%	-0.17%	-0.02%	0.57%	-0.51%	-0.76%	-1.07%
Book Value per Share	77.44	39.89	76.93	96.09	24.45	17.88	14.07	6.48	1.41	-0.03
Total Shareholders' Equity	4.73M	2.97M	6.32M	20.88M	17.23M	16.84M	26.49M	13.01M	3.17M	-211.88K
Common Stock	39.86K	49.11K	4.93K	29.43K	46.13K	91.77K	116.39K	2.02K	3.08K	12.57K
Retained Earnings	-87.66M	-94.67M	-101.4M	-111.37M	-127.35M	-154.44M	-171.27M	-185.56M	-206.22M	-216.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.45M	-1.52M	-1.58M	-1.61M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.1M	-7.08M	-6.36M	-9.08M	-13.01M	-16.95M	-13.47M	-15.23M	-7.29M	-8.6M
Operating CF Margin %	-4.34%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.08%	-0.39%	0.1%	-0.43%	-0.43%	-0.3%	0.21%	-0.13%	0.52%	-0.18%
Net Income	-11.71M	-7.01M	-6.73M	-9.91M	-15.57M	-26.43M	-15.71M	-14.29M	-20.66M	-10.57M
Depreciation & Amortization	71.15K	75.04K	65.8K	30.11K	62.62K	51.7K	41.24K	44.67K	27.39K	0
Stock-Based Compensation	1.03M	638.42K	560.48K	1.02M	553K	1.49M	1.69M	742.2K	1.02M	516.05K
Deferred Taxes	-1.28K	3.13K	0	0	0	0	-1.77M	0	0	0
Other Non-Cash Items	5M	-1.45M	-70.49K	12K	12K	7.9M	1.77M	-10.96K	10.3M	0
Working Capital Changes	502.37K	675.38K	-188.12K	-228.14K	1.93M	37.02K	512.14K	-1.72M	2.02M	1.45M
Change in Receivables	-5.51K	0	0	0	0	0	-6.99K	6.99K	0	0
Change in Inventory	117.68K	0	0	0	0	0	6.99K	0	0	0
Change in Payables	331.08K	446.04K	525.78K	225.31K	0	0	10.55K	0	0	-119.8K
Cash from Investing+	-101.23K	1.68M	0	-124.73K	-25.21K	0	-43.88K	-115.52K	-936.28K	0
Capital Expenditures	-102.51K	-27.18K	0	-124.73K	-25.21K	0	-43.88K	-127.52K	-1M	0
CapEx % of Revenue	0.09%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.28K	1.7M	0	0	0	0	0	12K	63.72K	0
Cash from Financing+	-159.95K	4.45M	8.45M	23.25M	11.1M	16.32M	23.14M	-494.92K	283.88K	5.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-58.67K	0	0	-1.12M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	1.97M	6.21M	23.31M	11.35M	5.18M	1.12M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.21M	-7.1M	-6.36M	-9.2M	-13.04M	-16.95M	-13.51M	-15.36M	-8.29M	-8.6M
FCF Margin %	-4.43%	-	-	-	-	-	-	-	-	-
FCF Growth %	0.08%	-0.36%	0.1%	-0.45%	-0.42%	-0.3%	0.2%	-0.14%	0.46%	-0.04%
FCF per Share	-85.23	-95.53	-77.51	-42.36	-18.50	-17.99	-7.18	-7.64	-3.68	-1.30
FCF Conversion (FCF/Net Income)	0.44x	1.01x	0.95x	0.92x	0.84x	0.64x	0.86x	1.07x	0.35x	0.81x
Interest Paid	0	0	0	0	7.3K	10.02K	0	9.29K	30.59K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-155.45%	-182.24%	-145.04%	-72.9%	-81.72%	-155.13%	-72.52%	-72.35%	-255.36%	-714.95%
Return on Invested Capital (ROIC)	-	-	-2184.64%	-1457.5%	-3213.29%	-84585%	-19448.14%	-972.3%	-1416.19%	-
Gross Margin	59.02%	-	-	-	-	-	-	-	-	-
Net Margin	-995.83%	-	-	-	-	-	-	-	-	-
Debt / Equity	0.01x	0.02x	0.01x	0.01x	0.06x	0.05x	0.03x	0.05x	0.10x	-
Interest Coverage	-151.98x	-2075.44x	-31.06x	-1727.27x	-2175.07x	-2493.35x	-1000.95x	-954.83x	-	-353.99x
FCF Conversion	0.44x	1.01x	0.95x	0.92x	0.84x	0.64x	0.86x	1.07x	0.35x	0.81x
Revenue Growth	25.12%	-100%	-	-	-	-	-	-	-	-

Revenue by Segment

	2022	2023
Grant	250K	250K
Grant Growth	-	0.00%

Frequently Asked Questions

Growth & Financials

Oragenics, Inc. (OGEN) grew revenue by 0.0% over the past year. Growth has been modest.

Oragenics, Inc. (OGEN) reported a net loss of $10.9M for fiscal year 2024.

Dividend & Returns

Oragenics, Inc. (OGEN) has a return on equity (ROE) of -714.9%. Negative ROE indicates the company is unprofitable.

Oragenics, Inc. (OGEN) had negative free cash flow of $8.4M in fiscal year 2024, likely due to heavy capital investments.